Home
Scholarly Works
Outcomes of patients (pts) with metastatic...
Conference

Outcomes of patients (pts) with metastatic urothelial carcinoma (mUC) following discontinuation of enfortumab-vedotin (EV): Emergence of a new unmet need.

Authors

Curran C; Pond GR; Kazakova V; Grivas P; Diamantopoulos LN; Alva AS; Su C; Jain RK; Tandon A; Zhang J

Volume

38

Publisher

LIPPINCOTT WILLIAMS & WILKINS

Publication Date

May 20, 2020

Name of conference

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Conference place

ELECTR NETWORK

Conference start date

May 29, 2020

Conference end date

May 31, 2020

Conference proceedings

JOURNAL OF CLINICAL ONCOLOGY

Issue

15

ISSN

0732-183X

Labels

Fields of Research (FoR)

Contact the Experts team